Charles Schwab Investment Management Inc. Has $2.03 Million Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Charles Schwab Investment Management Inc. boosted its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 223.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 569,185 shares of the company’s stock after purchasing an additional 393,202 shares during the period. Charles Schwab Investment Management Inc. owned 0.91% of Fulcrum Therapeutics worth $2,032,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. National Bank of Canada FI increased its stake in shares of Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after buying an additional 4,000 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Fulcrum Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after acquiring an additional 4,701 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Fulcrum Therapeutics in the 3rd quarter valued at about $62,000. Profund Advisors LLC bought a new position in shares of Fulcrum Therapeutics in the second quarter worth about $68,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Fulcrum Therapeutics during the second quarter worth approximately $82,000. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ:FULC opened at $4.42 on Tuesday. The firm’s 50 day simple moving average is $3.52 and its 200 day simple moving average is $5.89. Fulcrum Therapeutics, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $13.70. The company has a market capitalization of $238.41 million, a price-to-earnings ratio of -14.26 and a beta of 2.14.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Leerink Partners restated a “market perform” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, September 12th. Bank of America downgraded Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $10.00 to $2.00 in a research report on Thursday, September 12th. Cantor Fitzgerald cut Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a report on Thursday, September 12th. Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. Finally, Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the company from $22.00 to $3.00 in a research note on Thursday, September 12th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $9.33.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.